Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
|Podcasts|March 30, 2023
Bridging the Gap in Health Care Inequities: Considerations in Treatment Selection, Part 1
In part 1 of this 2-part series on health equity in the treatment of psoriasis, Ryan Haumschild, PharmD, and Bryan Buckley, DrPH, discuss how providers can address disparities in care, specifically with race, cultural, and ethnic backgrounds in mind.
Advertisement
In part 1 of this 2-part series on health equity in the treatment of psoriasis, Ryan Haumschild, PharmD, and Bryan Buckley, DrPH, discuss how providers can address disparities in care, specifically with race, cultural, and ethnic backgrounds in mind.
This podcast conversation is a follow-up to a panel discussion posted in December. You can watch the full panel, "
Advertisement
Related to this article
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
3
Myeloma Is Many Diseases, and Treatment Must Reflect That
4
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
5